|Laid down:||15 May 1945|
|Launched:||16 June 1947|
|Commissioned:||4 April 1949|
|Decommissioned:||31 October 1958|
|Fate:||Sold to Levin Metals Corporation of San Jose, Calif. on 22 February 1972|
|Length:||679 ft 6 in|
|Beam:||70 ft 8 in|
|Propulsion:||Machinery, 120,000 shp; Geared Turbines, 4 screws|
|Armament:||12 × 6"/47 DP, 24 × 3"/50 AA, 12 × 20 mm|
|Motto:||"NUNC PARATI SUMUS"|
The fourth USS Roanoke (CL-145) was laid down a week after the end of World War II in Europe, on 15 May 1945 by the New York Shipbuilding Corp., Camden, N.J.; launched 16 June 1947; sponsored by Miss Julia Ann Henebry; and commissioned at Philadelphia 4 April 1949, Capt. John D. Kelsey in command.
Following shakedown in the Caribbean, Roanoke undertook maneuvers in the Atlantic as a unit of the Battleship-Cruiser Force and on 6 January 1950 got underway to join the 6th Fleet in the Mediterranean for her first extended deployment. Returning to the United States in May, she alternated 6th Fleet deployments with operations in the western Atlantic until the summer of 1952 when she added a midshipman's cruise to Europe and the Caribbean to her schedule. Continuing to operate in the Battleship-Cruiser Force, U.S. Atlantic Fleet until the fall of 1955, Roanoke completed her sixth Mediterranean deployment in May, then prepared for transfer to the Pacific Fleet.
On 22 September 1955, Roanoke departed Norfolk, Va., for the Panama Canal. Homeported at Long Beach, she conducted nine Naval Reserve cruises and completed two WestPac cruises, May to December 1956 and September to October 1958, before decommissioning 31 October 1958. She was berthed at Mare Island until sold to the Levin Metals Corporation of San Jose, California on 22 February 1972.
Infinity Reports Preclinical Data for IPI-145 and Announces Initial Indications for Phase 2 Development in Inflammation
Jul 11, 2012; By a News Reporter-Staff News Editor at Biotech Week -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) reported preclinical data...
Infinity Reports Phase 1 Data Showing Encouraging Clinical Activity of IPI-145 across a Broad Range of Blood Cancers at the 12th International Conference on Malignant Lymphoma
Jul 08, 2013; By a News Reporter-Staff News Editor at Clinical Trials Week -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced Phase 1...
Infinity Updates on Phase 1 Data Showing Clinical Activity of IPI- 145 across a Broad Range of Blood Cancers at the 12th International Conference on Malignant Lymphoma
Jun 27, 2013; Infinity Pharmaceuticals, Inc. announced Phase 1 data from an ongoing study of IPI-145, its potent, oral inhibitor of...